Clinical Trial

Reducing Mortality in Adults With Advanced HIV Disease (REVIVE)

Study acronym: REVIVE
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
A double blinded, placebo-controlled, multicenter trial to evaluate effectiveness of azithromycin prophylaxis on mortality in advanced HIV.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-10-13; most recent amendment 2025-08-26.
Status change: Not Yet Recruiting → Recruiting 2023-05-25
Trial Details
NCT Number NCT05580666
Lead Sponsor Population Health Research Institute
Conditions HIV Disease Progression
Enrollment 8,000 participants
Start Date 2023-05-08
Primary Completion 2028-11-30 (estimated)
Study Completion 2029-05-31 (estimated)
Updated on ClinicalTrials.gov 2025-09-03